PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
610 episodes - English - Latest episode: about 19 hours ago - ★★★★★ - 7 ratingsPeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Shannon N. Westin, MD, MPH - New Horizons for Advanced Endometrial Cancer Treatment: Utilizing Innovative Immunotherapies and Other Novel Approaches
March 01, 2023 23:00 - 49 minutes VideoGo online to PeerView.com/GEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For patients with recurrent or advanced endometrial cancer, tremendous therapeutic gains have been realized with the incorporation of immune checkpoint inhibitors. Monotherapy and combination approaches have had multiple regulatory approvals in the second-line setting and clinical trials assessing use in the frontline setting are underway. In this CME activity,...
John C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCL
March 01, 2023 23:00 - 48 minutes VideoGo online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety cons...
Nikhil C. Munshi, MD - The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes
February 02, 2023 23:00 - 1 hour VideoGo online to PeerView.com/KTZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared to safely integrate BCMA-targeting options into the care plan for your relapsed/refractory multiple myeloma (MM) patients, including treatment with antibodies, bispecific agents, and CAR-T cell therapy? Find out in this expert-led MasterClass and Case Forum recorded at the Annual Hematology Meeting. Watch our experts as they offer learner...
Nathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLC
February 02, 2023 23:00 - 1 hour VideoGo online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have bec...
Prof. Hans Gelderblom, MD - New Evidence Now for Targeted Therapy in TGCT
January 27, 2023 23:00 - 13 minutes VideoGo online to PeerView.com/DNP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What are your skills in managing tenosynovial giant cell tumors (TGCT)—particularly in light of updated phase 3 evidence supporting systemic treatment? Find out in this final part of an educational series on TGCT, where an expert in the field reviews current standards of care and provides updates from a major clinical trial that supports the use of targeted opt...
Grzegorz (Greg) Nowakowski, MD - Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care
January 27, 2023 23:00 - 1 hour VideoGo online to PeerView.com/ENP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Did you miss the PeerView DLBCL Seminar & Tumor Board at the Annual Hematology Meeting in New Orleans or want to revisit this important educational event? Access this program to watch a panel of experts debate the emergence of potent, antibody-based treatment platforms for patients with DLBCL, including novel CD19-directed antibodies, antibody-drug conjugates, ...
Prof. John G. Gribben, MD, DSc - Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment
January 27, 2023 23:00 - 2 hours VideoGo online to PeerView.com/NMB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current chronic lymphocytic leukemia (CLL) management tool kit is expanding to include covalent and non-covalent BTK inhibitors, BCL-2 inhibitors, chemo-sparing combinations, and cellular therapies—are you prepared for this challenging and exciting new era in care? This “Seminars & Tumor Board” activity, adapted from our recent live event preceding the 64th...
Erika Hamilton, MD - Clarifying the Complexities of the Expanding Treatment Options for Advanced- and Early-Stage HR+/HER2- Breast Cancer
January 27, 2023 23:00 - 1 hour VideoGo online to PeerView.com/YNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Endocrine therapy, typically with an aromatase inhibitor or fulvestrant plus a CDK4/6 inhibitor, is a mainstay for the management of HR+/HER2- metastatic breast cancer, but many questions still remain about the nuances of optimal use of these and other agents in first- and later-line settings. Furthermore, a number of investigational therapies are showing great...
Guillermo Garcia-Manero, MD - The Future is Now in MDS: Integrating Innovative, Risk-Adapted Therapies Into Patient Management
January 11, 2023 23:00 - 1 hour VideoGo online to PeerView.com/PMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It’s a new era for treatment of myelodysplastic syndrome (MDS), one where clinicians increasingly have an opportunity to customize care for every patient according to risk factors and other baseline features. Are you prepared for the tailored use of erythroid maturation agents, fixed-dose combinations, newer targeted agents, and novel immune-based strategies? F...
Petros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits All
January 06, 2023 23:00 - 1 hour VideoGo online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug ...
Professor Peter Schmid, FRCP, MD, PhD - TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted Treatments
January 06, 2023 23:00 - 51 minutes VideoGo online to PeerView.com/ZDH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibody–drug conjugates (ADCs) represent a much-needed addition of highly effective agents with unique mechanisms of action to the breast cancer treatment arsenal. TROP2-targeted ADC therapy already has an established role in triple-negative breast cancer (TNBC), and it has recently also demonstrated activity in HR+/HER2- breast cancer. Further investiga...
Rana R. McKay, MD, Alicia K. Morgans, MD, MPH - Alicia K. Morgans, MD, MPH - Case by Case: Maximizing Personalized Approaches to Prostate Cancer
January 06, 2023 23:00 - 57 minutes VideoGo online to PeerView.com/YGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The expanding therapeutic landscape for prostate cancer has provided new opportunities for oncology and urology professionals to improve outcomes through individualized patient care. With new and emerging strategies in both the hormone-sensitive and -resistant settings, treatment of patients with prostate cancer requires knowledge of next-generation anti-androg...
Steven Brem, MD - Setting Our Sights on Improved Outcomes in Glioblastoma: State-of-the-Art Care With Tumor Treating Fields and Other Innovative Approaches
January 06, 2023 23:00 - 1 hour VideoGo online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for pat...
Javid Moslehi, MD - Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Team-Based Strategies for Risk Assessment, Diagnosis, and Management of Myocarditis and Other Cardiac Immune-Related Adverse Events
January 04, 2023 23:00 - 1 hour VideoGo online to PeerView.com/SFP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) have had a strikingly positive impact on the treatment of a range of cancer types by blocking intrinsic downregulators of the immune response to increase antitumor immunity. A number of ICIs and ICI-based combinations have been approved for use in many solid and liquid malignancies, and intense research efforts promise to exp...
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 8: VTE in Cancer: How Concerning Is It and What Do We Do About It?
December 19, 2022 23:00 - 11 minutes VideoGo online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidenc...
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 7: How Should VTE Be Managed in Patients With Obesity?
December 19, 2022 23:00 - 10 minutes VideoGo online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidenc...
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 6: What Is Real-World Evidence and How Is It Relevant and Important in VTE?
December 19, 2022 23:00 - 6 minutes VideoGo online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidenc...
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 5: Knocking Down Barriers in Transitions of Care
December 19, 2022 23:00 - 12 minutes VideoGo online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidenc...
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 4: How Can We Talk About VTE to Our Patients?
December 19, 2022 23:00 - 9 minutes VideoGo online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidenc...
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 3: Anticoagulation: When to Use It, With What, and for How Long?
December 19, 2022 23:00 - 13 minutes VideoGo online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidenc...
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 2: Tools for Unmasking VTE Quickly
December 19, 2022 23:00 - 10 minutes VideoGo online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidenc...
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 1: Why Are We Talking About VTE?
December 19, 2022 23:00 - 6 minutes VideoGo online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidenc...
Sumanta Kumar Pal, MD, FASCO - RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World
December 19, 2022 23:00 - 58 minutes VideoGo online to PeerView.com/WYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Robust clinical evidence supports effective upfront treatment platforms based on novel multitargeted tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitor therapies, now standard for patients with renal cell carcinoma (RCC). New options across the disease spectrum allow more patients with metastatic, refractory, or high-risk localized disease to ben...
Catherine M. Broome, MD - Following the Diagnostic Pathway for Cold Agglutinin Disease
December 19, 2022 23:00 - 30 minutes VideoGo online to PeerView.com/UHP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the main clinical features and pathophysiologic mechanisms of autoimmune hemolytic anemia (AIHA), as well as appropriate strategies to differentiate cold agglutinin disease from other forms of AIHA in providing optimal care for patients. Upon completion of this activity, participants should be better able to: Recognize the ...
Amit Singal, MD, MS - It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration and Modern Therapeutics
December 19, 2022 23:00 - 1 hour VideoGo online to PeerView.com/QYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the choice of regimens for patients with hepatocellular carcinoma (HCC) continues to expand with new standard-of-care therapies for advanced disease, and emerging innovative locoregional and multimodal strategies for early- and intermediate-stage disease, clinicians who treat liver cancer have increased opportunities to collaborate with colleagues and improv...
Daniel J. George, MD - Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?
November 30, 2022 23:00 - 48 minutes VideoGo online to PeerView.com/ZYP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This educational program exposes learners to the science that supports the use of GnRH antagonists for appropriate patients with advanced prostate cancer and will enhance their ability to select optimal ADT regimens based on CV risk and other clinically-relevant factors, and optimize CV care and outcomes during ADT. Through a collection of short, focused educat...
Caron Jacobson, MD - Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care
November 30, 2022 23:00 - 1 hour VideoGo online to PeerView.com/XZA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique video-based activity will offer learners a window into practice by featuring a series of expert-led lectures that will seamlessly link the latest scientific evidence on CAR-T therapy across a range of hematologic malignancies with panel-based insights on clinical decision-making. Each session will include a Tumor Board segment designed to reflect re...
Erik P. Sulman, MD, PhD - Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors
November 22, 2022 23:00 - 1 hour VideoGo online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality as...
Alicia K. Morgans, MD, MPH - Creating a Roadmap for Modern Prostate Cancer Treatment: How to Use the Most Recent Evidence on Novel Therapeutic Strategies and Shared Decision-Making to Personalize Patient Care
November 17, 2022 23:00 - 1 hour VideoGo online to PeerView.com/XGS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Two experts highlight how a prostate cancer care team can use the latest clinical evidence, treatment guidelines, and consensus recommendations to improve outcomes for patients with prostate cancer and will give practical insights on applying next-generation anti-androgen agents, PARP inhibitors, and chemotherapy to the prostate cancer treatment landscape. By p...
Nasser Altorki, MD - Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right
November 17, 2022 23:00 - 53 minutes VideoGo online to PeerView.com/CDB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Research and clinical practice continue to build on the success achieved to date with cancer immunotherapy and to refine rational strategies to expand its benefits to more patients, including in curative-intent settings. Immunotherapy has started to radically transform the multimodal approach to treatment of resectable stage I-III NSCLC. Recently, highly positi...
Morie A. Gertz, MD - Don’t Miss the Rare When Diagnosing and Treating Autoimmune Hemolytic Anemia: Focus on CAD
November 14, 2022 23:00 - 30 minutes VideoGo online to PeerView.com/MVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies that target the classical complement pathway and individualizing treatment plans for patients living with CAD. Upon completion of this activity, participants should be better able to: Describe the consequences of inhibiting complement C1s as long-term therapy for CAD, particularly on symptoms influenced predomina...
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations
November 08, 2022 23:00 - 59 minutes VideoGo online to PeerView.com/RJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed both in biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. A growing number of new agents and combinations have become available for pati...
Naval Daver, MD, Amir T. Fathi, MD - The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes
October 28, 2022 23:00 - 1 hour VideoGo online to PeerView.com/NQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel in...
Marina Chiara Garassino, MD - Are You Prepared for the New Wave of ADCs in NSCLC? Innovative Approaches and Practical Considerations in Targeting HER2, HER3, TROP2, and Other Alterations in Advanced Lung Cancer
October 28, 2022 23:00 - 56 minutes VideoGo online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3...
Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions
October 28, 2022 23:00 - 1 hour VideoGo online to PeerView.com/XXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently validated and emerging therapies are providing new hope for patients with small cell lung cancer (SCLC). In patients with extensive-stage or metastatic disease, regulatory approvals of chemo-immunotherapy combinations, the transcription inhibitor lurbinectedin, and the myeloprotective agent trilaciclib have led to new guideline-recommended standards of...
Sagar Lonial, MD, FACP - An "Off-the-Shelf" Approach for Myeloma Care: Visualizing the Present and Future of BCMA Antibodies
October 28, 2022 23:00 - 32 minutes VideoGo online to PeerView.com/EGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to integrate novel "off-the-shelf" BCMA-directed antibody-based therapies into the treatment of patients with multiple myeloma (MM)? This highly visual educational activity illustrates the mechanism of action for targeting BCMA in relapsed/refractory MM (RRMM) and brings to life the latest data on the use of antibody–drug conjugates (ADCs) and eme...
Sagar Lonial, MD, FACP - Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies
October 28, 2022 23:00 - 54 minutes VideoGo online to PeerView.com/FMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting...
Praneetha Thulasi, MD, Jonathan L. Kaufman, MD - The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular Toxicity
October 28, 2022 23:00 - 57 minutes VideoGo online to PeerView.com/AHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to care for your patients with multiple myeloma (MM) who are experiencing ocular complications associated with the latest myeloma treatments? Ophthalmologists play an important in the care of myeloma, and in this PeerView MasterClass & Ophthalmology Case Forum an ophthalmologist and an oncologist highlight the importance of the ophthalmology and o...
Scott T. Tagawa, MD, MS, FACP - Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates
October 28, 2022 23:00 - 40 minutes VideoGo online to PeerView.com/VRE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Metastatic urothelial carcinoma (UC) is a devastating illness with limited treatment options, especially for patients who have been previously treated with platinum-based chemotherapy and anti–PD-1/L1 therapy. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. The activity also features a patie...
Brendon M. Stiles, MD - Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings
October 28, 2022 23:00 - 41 minutes VideoGo online to PeerView.com/WRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Approximately 40% of patients with early-stage lung cancer experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Management of patients with NSCLC should be individualized based on a number of factors, including the molecular profile of the patient’s tumor and the benefits and limitation...
Nicole Lamanna, MD / Deborah M. Stephens, DO - Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices
October 28, 2022 23:00 - 59 minutes VideoGo online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to a...
Guillermo Garcia-Manero, MD; Gail J. Roboz, MD - The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes
October 20, 2022 23:00 - 1 hour VideoGo online to PeerView.com/EEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists’ case-based...
Professor Aleix Prat, MD, PhD - Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients
October 20, 2022 23:00 - 1 hour VideoGo online to PeerView.com/FGB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. HER2-targeting therapies have led to remarkable improvements in patients with HER2-positive early and advanced breast cancer. Recently, novel antibody–drug conjugates (ADCs) and other HER2-targeting therapies have also demonstrated impressive activity in patients with HER2-low breast cancer, who account for approximately 40%-50% of patients with breast cancer a...
Sara M. Tolaney, MD, MPH - Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer
October 20, 2022 23:00 - 55 minutes VideoGo online to PeerView.com/VMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selecti...
Javier Cortes, MD, PhD - SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Addressing Unmet Needs, Establishing New Standards of Care, and Improving Patient Outcomes With Novel ER-Targeting Therapies
October 19, 2022 23:00 - 1 hour VideoGo online to PeerView.com/DFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Breast cancer is a heterogeneous disease comprising different subtypes, with estrogen receptor positive (ER+) being the most common subtype. Endocrine therapy (ET) is the primary treatment in ER+ breast cancer, which includes different strategies that directly or indirectly modify estrogen production. CDK4 and 6 inhibition as well as PI3K inhibition have improv...
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease
October 04, 2022 23:00 - 59 minutes VideoGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum se...
Marcia S. Brose, MD, PhD, FASCO - Optimizing NTRK Fusion Testing and TRK Inhibition in Thyroid Cancer: Team-Based Approaches for Enhanced Outcomes
October 04, 2022 23:00 - 37 minutes VideoGo online to PeerView.com/QKA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this inExchange from PeerView, a multidisciplinary team of experts from oncology, endocrinology, and pathology discuss the advantages of a team-based approach to NTRK fusion testing and TRK inhibition in thyroid cancer. In this 30-minute learning opportunity, you’ll hear how endocrinologists can lead the interprofessional charge to enhance outcomes by optimi...
Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies
September 22, 2022 23:00 - 35 minutes VideoGo online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will det...
Alexander Drilon, MD - Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC
September 19, 2022 23:00 - 1 hour VideoGo online to PeerView.com/CNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC. Upon completion of this activity, participants should be better able to: Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and t...
Ritu Salani, MD, MBA - Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence
September 06, 2022 23:00 - 36 minutes VideoGo online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data ...